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Key Points
•Blinatumomab mainte-
nance therapy demon-
strated evidence of
extended survival out-
come in patients with
R/R ALL.
•Most responders after
induction maintained
their responses with
additional cycles of bli-
natumomab; some new
responses were
achieved in the later
cycles.
In a phase 3 clinical study of heavily pretreated adults with relapsed/refractory (R/R) acute
lymphoblastic leukemia (ALL), overall survival (OS) following blinatumomab, a BiTE
(bispecific T-cell engager) immunooncology therapy, was significantly improved vs
chemotherapy following induction (cycles 1 to 2). Here we report the efficacy and safety of
those who received additional cycles of blinatumomab. Blinatumomab was administered as
a continuous IV infusion for 4 weeks in a 6-week cycle. Patients who achieved a bone
marrow response (#5% blasts) or complete remission (full, partial, or incomplete
hematological recovery) during induction could receive additional cycles of blinatumomab.
OS and relapse-free survival (RFS) for consolidation (cycles 3 to 5) vs no consolidation, and
maintenance (cycles $6) vs no maintenance were analyzed using Simon-Makuch and
Mantel-Byar odds ratios. Of 267 patients who received blinatumomab induction, 86 (32%)
entered consolidation and 36 (13%) entered maintenance. Evidence of longer OS was
demonstrated among the maintenance group compared with no-maintenance (median OS
[95% confidence interval, CI]: not reached for maintenance vs 15.5 months for no
maintenance). Median RFS (months; 95% CI) was numerically longer among maintenance
group (14.5; 7.1 to 21.9) compared with no-maintenance (9.8; 8.5 to 11.1). A lower incidence
of adverse events was seen during maintenance (72.2%) compared with induction (97.2%)
and consolidation (86.1%). Adults with R/R ALL who achieved remission following
blinatumomab induction had longer survival on continuation therapy than those who
discontinued blinatumomab early, supporting the use of blinatumomab as long-term
therapy. No new safety signals were reported. This trial was registered at www.
clinicaltrials.gov as #NCT02013167.
Introduction
Despite up to 80% of adults with acute lymphoblastic leukemia (ALL) achieving complete remission (CR)
following traditional chemotherapy, 45% of adults will relapse or remain refractory. Among these patients,
the prognosis has historically been poor with median overall survival (OS) of 2 to 8 months and 5-year OS
rates of,10%.1,2 In recent years, significant advances in our understanding of ALL pathogenesis have led
to the development of promising treatment options beyond conventional chemotherapy, such as those
targeting cell surface antigens (eg, inotuzumab ozogamicin, blinatumomab, chimeric antigen receptor
T-cell therapy).3
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Blinatumomab is a CD19 BiTE (bispecific T-cell engager) immunoon-
cology therapy that activates endogenous cytotoxic T cells to kill target
B cells. Blinatumomab is indicated for the treatment of adults and
children with relapsed/refractory (R/R) B-cell precursor (BCP)
ALL and for patients with minimal residual disease (MRD) ALL,
defined as at least 1023 (0.1%) leukemic cells detected by quantitative
polymerase chain reaction (PCR).4 In a randomized phase 3 study, OS
with blinatumomab was superior to standard-of-care chemotherapy
(SOC) in patients with R/R ALL.5 Patients who completed 2 cycles of
induction therapy with blinatumomab could proceed to hematopoietic
stem cell transplantation (HSCT) or opt for additional blinatumomab
consolidation and maintenance cycles, provided they continued in
hematological remission.5 Here we report the survival outcomes,
remission rates, and safety of patients who received blinatumomab
continuation therapy.5,6 OS and relapse-free survival (RFS) are
compared between patients who received consolidation/maintenance
cycles against thosewhowere eligible but did not receive such cycles.
Methods
Full details regarding study (NCT02013167) methodology have
been previously published.5 Here we present the analysis using
final data from 3 January 2014 to 14 March 2017. The study and all
amendments were reviewed by an independent ethics committee/
institutional review board at each center.
Trial design and patients
In brief, this was an international, randomized, open-label, phase 3
study of blinatumomab vs SOC in adults with R/R Philadelphia
chromosome–negative (Ph2) BCP-ALL. Eligible patients were
refractory to primary induction or salvage therapy with intensive
combination chemotherapy, first relapse within first remission
,12 months, second or greater relapse, or had relapse any time
after allogeneic HSCT. Additional criteria included .5% bone
marrow blasts, Eastern Cooperative Oncology Group (ECOG)
performance status #2, and adequate organ function. Key
exclusion criteria have been previously reported.5
Treatments
During induction (cycles 1 to 2), blinatumomab was administered as
a continuous IV infusion 4 weeks on and 2 weeks off (1 cycle) at an
initial dose of 9 mg per day for days 1 to 7 of cycle 1, and then the
dose was stepped up to 28 mg per day for days 8 to 28 of cycle 1
and all days of subsequent cycles. Patients who achieved a bone
marrow response (#5% bone marrow blasts) or CR, complete
remission with partial hematological recovery/complete remission
with incomplete hematological recovery (CRh/CRi) within the first 2
cycles could receive additional consolidation (cycles 3 to 5) and
maintenance cycles (cycles 6 and above). Maintenance cycles were
4 weeks on and 8 weeks off (Figure 1). Patients discontinued
blinatumomab if one of the following occurred: HSCT, investigator
discretion, toxicity, relapse, or use of protocol-excluded medica-
tions.5 Dexamethasone premedication was required prior to each
infusion and dose step to prevent infusion-related reactions and
cytokine release syndrome (CRS). Safety follow-up visit occurred
30 days after the last dose of protocol-specified therapy, and long-
term follow-up occurred every 3 months as specified in the protocol.
Response assessments
Hematological remission was defined as having#5% blasts in bone
marrow, no evidence of disease, and peripheral blood count
recovery as follows: CR was defined as full recovery with platelets
.1003 103/mL and absolute neutrophil count (ANC) .1 3 103
/mL; CRh was defined as platelets .503 103/mL and ANC .0.5
3 103/mL; and CRi was defined as platelets .1003 103/mL or
ANC .1 3 103/mL. In addition, MRD remission was defined as
MRD level ,1024 by multicolor flow cytometry or real-time
quantitative PCR.
Statistical analysis
End points included OS (time from randomization until death), RFS
(time from first CR/CRh/CRi to relapse or death), hematological
response (CR/CRh/CRi), MRD response, and adverse events by
treatment phase (ie, induction, consolidation, and maintenance).
Descriptive response rates and patient incidence of treatment-
emergent adverse event are provided for those who received
blinatumomab consolidation and maintenance cycles.
Because patients had to survive and be in remission long enough to
receive consolidation and maintenance cycles, simple comparisons
of all patients would have a survivor time bias in favor of the
consolidation and maintenance groups and against the no-
consolidation and no-maintenance groups. Thus, only patients
alive and who have the opportunity to receive these additional
cycles (who may or may not have) were included in OS analyses
(eg, those alive and in remission at month 3 were included in
consolidation vs no-consolidation comparison; those alive and in
remission at month 7 were included in the maintenance vs no-
maintenance comparison). All induction responders were included
in the consolidation vs no-consolidation comparison, but only
patients in remission at least 5 months after first CR/CRh/CRi
Randomization 2:1
(blinatumomab:SOC) 
Inductiona
(up to 2 cycles)
4 weeks on, 2 weeks off 
Consolidationb
(up to 3 cycles)
4 weeks on, 2 weeks off 
Maintenancec,d
(up to 12 months)
4 weeks on, 8 weeks off
Safety & long-term follow-up
Figure 1. Induction, consolidation, and maintenance study design (blinatu-
momab group). aIn induction cycle 1 week 1, 9 mg per day, and 28 mg per day
thereafter by continuous infusion. bObserved cycle 3 day 1 varied between day 85
and day 131 on study. cObserved maintenance day 1 varied between day 211
and day 266 on study. dMaintenance therapy was discontinued in the case of
transition to HSCT, investigator discretion, toxicity, relapse, or use of protocol-
excluded medications.
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were included in the maintenance vs no-maintenance comparison.
Because of the potential of treatment interruptions in early cycles,
patients could start consolidation andmaintenance cycles at different
times (Figure 1). Simon-Makuch curves7 and Mantel-Byar odd ratios8
were used in the OS and RFS comparisons to correctly assign
patients to comparison groups. These methods check at each time
point (posteligibility cutoff date) if the patient has started consolida-
tion or maintenance and are attributed accordingly. For example, the
number of patients in the Simon-Makuch curve varies as patients who
start in the no-consolidation group switch to the consolidation group
when they start cycle 3. The OS and RFS analyses were not
censored at HSCT as there would not have been enough observed
death or relapse events for inference if the OS and RFS analyses had
been censored for HSCT.
Results
Study population
In this study of 405 patients, 271 were randomized to blinatumomab
and 267 received blinatumomab. Of the 119 patients who achieved
CR/CRh/CRi during induction and were eligible for consolida-
tion, 86 (32%) patients received consolidation cycles; 36 (13%)
patients received maintenance cycles; and 11 (4%) patients
completed maintenance (Figure 2). Baseline characteristics of
patients receiving blinatumomab by randomization, consolidation,
and maintenance phases are summarized in Table 1. Overall, the
subset of patients who proceeded to maintenance had a higher rate
of prior HSCT treatment and posttransplant relapse than those in
the larger subset who entered randomization and received
consolidation.
OS
For OS consolidation vs no-consolidation, 115 patients alive and in
remission at month 3 were included in the comparison (Figure 3A);
82 patients eventually received consolidation and 34 did not. For
OS maintenance vs no-maintenance, 78 patients alive in remission
at month 7 were included in the comparison (Figure 3B). Of these,
36 eventually received maintenance cycles. Additional details can
be found in supplemental Figure 1.
Median OS was 16.6 months (95% confidence interval [CI], 13.6-
19.6) in the consolidation group and 13.0 months (95% CI, not
estimable) in the no-consolidation group, with a relative odds ratio of
0.71 (95% CI, 0.38-1.32) (Figure 3A). Median OS was not reached
at the end of the study in patients who received maintenance and
15.5 months (95% CI, not estimable) among those who did not
Blinatumomab
271 randomized
4 never received study treatment
 1 patient request
 2 deaths
 1 protocol-specified criteria
Induction (cycles 1–2)
267 (99%) entered
induction
181 discontinued treatment
 5 patient requests
 13 deaths
 35 adverse events
 128 protocol-specified criteria
Consolidation (cycles 3–5)
86 (32%) entered
consolidation
50 discontinued treatment
 1 patient request
 1 death
 3 adverse events
 45 protocol-specified criteriaa
Maintenance (cycles  6)
36 (13%) entered
maintenance
25 discontinued treatment
 1 patient request
 1 death
 5 adverse events
 18 protocol-specified criteriab
11 (4%) reached end
of maintenance
period
Figure 2. Study consort diagram (blinatumomab group). aIntention to receive HSCT (n 5 18), intention to receive treatment other than allogeneic HSCT (n 5 1), relapse
(n 5 25), failure to achieve CR/CRh/CRi in first 2 cycles (n 5 1). bIntention to receive HSCT (n 5 5), intention to receive treatment other than allogeneic HSCT (n 5 4),
relapse (n 5 9).
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receive maintenance, with a relative odds ratio of 0.37 (95% CI,
0.16-0.88) indicating a 63% reduction in the risk of death for
maintenance (Figure 3B). This estimates an effect of OS benefit
from maintenance cycles among patients who are alive long enough
to receive such cycles.
RFS
For the RFS consolidation comparison, 119 patients who achievedCR/
CRh/CRi during the first 2 cycles were included in the consolidation
vs no-consolidation comparison. Of these, 82 eventually received
consolidation cycles and 37 did not. For the RFS maintenance
comparison, 63 remained in remission for 5 months from first CR/
CRh/CRi and were included in the analysis. Of these, 34 eventually
received maintenance cycles and 29 did not. Additional details can
be found in supplemental Figure 1.
Median RFS was 7.6 months (95% CI, 3.7-11.6) in the consolidation
group and 8.8 months (95% CI, 0-10.42) in the no-consolidation
group, with a relative odds ratio of 0.94 (95% CI, 0.53-1.66;
Figure 4A). In the maintenance comparison, the median RFS was
14.5 months (95% CI, 7.1-21.9) in the maintenance group and
9.8 months (95% CI, 8.5-11.1) in the no-maintenance group, with
a relative odds ratio of 0.48 (95% CI, 0.22-1.03; Figure 4B).
Best responses for patients receiving blinatumomab
Rates of hematological response were stable between induction
and consolidation phases. Among the 86 patients who started
consolidation, 69 (80.2%) and 63 (73.3%) had CR during induction
and consolidation, respectively; a total of 84 (97.7%) and 71
(82.6%) patients had CR/CRh/CRi (Table 2). Rates of MRD
response among those who had evaluable MRD assessment were
also stable between induction and consolidation phases, with 44
out of 72 (61.1%) and 29 out of 49 (59.1%) patients having MRD
CR during induction and consolidation, respectively (Table 2).
Among the 36 patients who started maintenance, best responses
were assessed during induction, consolidation, and maintenance,
with 26 (72.2%), 34 (94.4%), and 30 (83.3%) having CR,
respectively (Table 2). Best MRD responses assessed during
induction, consolidation, and maintenance identified 22 out of 30
(73.3%), 21 out of 23 (91.3%), and 8 out of 14 (57%) patients
having MRD CR, respectively (Table 2). Additional details of the
change in hematological and MRD responses before vs during
Table 1. Demographic and baseline characteristics
Blinatumomab randomization (N 5 271) Blinatumomab consolidation (N 5 86) Blinatumomab maintenance (N 5 36)
Sex, n (%)
Male 162 (60.0) 43 (50.0) 18 (50.0)
Female 109 (40.0) 43 (50.0) 18 (50.0)
Race, n (%)
White 228 (84.0) 72 (83.7) 33 (91.7)
Asian 19 (7.0) 7 (8.1) 2 (5.6)
Black (or African American) 5 (2.0) 2 (2.3) 0 (0)
American Indian or Alaska Native 0 (0) 1 (1.2) 0 (0)
Other 19 (7.0) 4 (4.7) 1 (2.8)
Median age, y (range) 37 (18-80) 38.5 (19-80) 34 (19-80)
Age group, y, n (%)
,35 124 (46.0) 38 (44.2) 19 (52.8)
35 to 54 80 (30.0) 26 (30.2) 12 (33.3)
55 to 64 34 (13.0) 9 (10.5) 2 (5.6)
$65 33 (12.0) 13 (15.1) 3 (8.3)
ECOG performance status, n (%)
0 96 (35.4) 38 (44.2) 13 (36.1)
1 134 (49.4) 37 (43) 19 (52.8)
2 41 (15.1) 11 (12.8) 4 (11.1)
.2 0 (0) 0 (0) 0 (0)
Patients with prior HSCT, n (%) 94 (35.0) 38 (44.2) 24 (66.7)
Patients who relapsed after HSCT, n (%) 91 (34.0) 36 (41.9) 23 (63.9)
Prior number of salvage regimens, n (%)
0 114 (42.0) 46 (53.5) 20 (55.6)
1 91 (34.0) 22 (25.6) 11 (30.6)
2 45 (17.0) 13 (15.1) 3 (8.3)
3 14 (5.0) 3 (3.5) 2 (5.6)
.3 7 (3.0) 2 (2.3) 0 (0)
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consolidation or maintenance can be found in supplemental Tables
2A-B and 3A-B.
Transplant
Of 86 patients who entered consolidation, 23 went on to receive
HSCT with median time to HSCT of 178 days (119 to 373). Among
the 44 HSCT without consolidation, median time to HSCT is
94.5 days (38 to 204). Of 36 patients who entered maintenance, 4
patients went on to receive HSCT with the median time to HSCT of
340 days (281 to 373). Among the 63 HSCT without maintenance,
median time to HSCT is 111 days (38 to 204).
Overall, patients receiving maintenance were less likely to have
HSCT after blinatumomab than those not receiving maintenance
(11.1% vs 26.8%, respectively; supplemental Table 1).
Adverse events
Treatment-emergent adverse events of interest (EOIs) in patients
receiving maintenance cycles were compared across induction,
consolidation, and maintenance (Table 3). Reported EOIs de-
creased from 97.2% to 86.1% to 72.2% of patients in induction,
consolidation, and maintenance, respectively. Grade $3 adverse
events were reported in 83.3%, 52.8%, and 38.9% of patients in
induction, consolidation, and maintenance, respectively. The grade
$3 events of most interest were neurotoxicities and CRS. Events
due to neurotoxicities were reported in 11.1% of patients in
induction, 0% in consolidation, and 11.1% in maintenance, whereas
CRS was reported in 5.6% in induction, 0% in consolidation, and
2.8% in maintenance. Other grade$3 adverse events for induction,
consolidation, and maintenance included neutropenia (44.4%,
33.3%, and 5.6% of patients, respectively), cytopenia (61.1%,
33.3%, 16.7%), decreased immunoglobulins (8.3%, 2.8%, 5.6%),
elevated liver enzyme (13.9%, 2.8%, 2.8%), and infusion reaction
considering duration (8.3%, 0%, 0%). On the other hand, infections
(16.7%, 22.2%, 22.2%) and lymphopenia (0%, 2.8%, 5.6%) of
grade $3 occurred more often during the later cycles. Serious
adverse events were reported in 30.6% of patients in induction and
consolidation, and in 36.1% of patients in maintenance. EOIs (any
grade) are summarized in supplemental Table 4.
Discussion
As previously reported, blinatumomab induction (cycles 1 to 2)
resulted in significantly longer OS compared with SOC in adults
with R/R BCP-ALL.5 Here we report the study outcomes for those
patients entering consolidation (cycles 3 to 5) and maintenance
(cycles $6) treated with blinatumomab. OS and RFS were
numerically longer with consolidation therapy vs no-consolidation
therapy (ie, stopping blinatumomab after induction), and improved
survival outcomes were achieved for patients with maintenance
therapy compared with no-maintenance therapy (ie, stopping
A
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Figure 3. Simon-Makuch plot for OS. (A) Analysis includes 115 patients alive
and in CR/CRh/CRi at month 3 (from randomization), of which, 82 patients
eventually received consolidation cycles (4 other consolidations patients either die or
relapse before month 3 and were not included in this analysis). Median OS is
13.0 months in the no-consolidation group and 16.6 (13.6 to 19.6) months in the
consolidation group. (B) Analysis includes 78 patients alive and in CR/CRh/CRi
at month 7 (from randomization), of which, 36 patients eventually received mainte-
nance cycles. Median (95% CI) is 15.5 months in the no-maintenance group and
not reached in the maintenance group. OR, odds ratio.
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Figure 4. Simon-Makuch plot for RFS. (A) Analysis includes 119 patients in CR/
CRh/CRi from date of first response, of which, 82 eventually received consolidation
cycles (4 other consolidation patients did not achieve CR/CRh/CRi in first 2 cycles
and were not included in in this analysis). Median (95% CI) is 8.8 (7.6 to 9.9)
months in the no-consolidation group and 7.6 (3.7-11.6) months in the consolidation
group. (B) Analysis includes 63 patients alive and in CR/CRh/CRi 5 months after
first hematological response, of which, 34 eventually received maintenance cycles
(2 other maintenance patients relapse before 5 months and were not included in
this analysis). Median (95% CI) is 9.8 (8.5-11.1) months in the no-maintenance
group and 14.5 (7.1-21.9) months in the maintenance group.
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blinatumomab after consolidation). A large number of patients who
achieved a best hematological response of CR were able to
maintain their responses with additional cycles of blinatumomab.
The safety profile of blinatumomab across induction, consolidation,
and maintenance phases was generally consistent with that seen in
other studies, with the incidence of most adverse events decreasing
with additional exposure to blinatumomab.9,10 Given the tolerability
and efficacy of blinatumomab in patients receiving consolidation
and maintenance therapy, blinatumomab may be an important
therapeutic option to consider for long-term treatment.
An important limitation of this ad hoc analysis is the small sample
size of 86 patients from consolidation and 36 patients from
maintenance. The small sample size did not provide sufficient power
to detect an OS or RFS benefit from both consolidation and
maintenance cycles of blinatumomab. However, the evidence of OS
improvement was found in patients who received maintenance
compared with those who did not, despite being eligible. As the
small number of patients also made censoring at HSCT not feasible,
any favorable effects of additional blinatumomab cycles might have
been dampened due to the potential benefit of HSCT in those
patients who received HSCT but not additional blinatumomab
cycles.
In conclusion, these findings suggest that long-term blinatumomab
therapy has the potential to help some patients achieve and
maintain a hematological CR. However, because many patients
were not assessed for MRD response in this study, it is not possible
to interpret the effect of extended blinatumomab therapy on
molecular remission. However, additional blinatumomab mainte-
nance cycles were found to prolong OS and trended toward longer
remission duration. Therefore, blinatumomab may be a suitable
option for long-term therapy with a manageable safety profile, but
larger studies are warranted to confirm these findings.
Table 2. Best hematological and MRD response across phases
Patients who started consolidation (N 5 86) Patients who started maintenance (N 5 36)
During induction
(cycles 1 to 2)
During consolidation
(cycles 3 to 5)
During induction
(cycles 1 to 2)
During consolidation
(cycles 3 to 5)
During induction 1
consolidation
During maintenance
(cycles ‡6)
Best response, n (%)
CR 69* (80.2) 63 (73.3) 26 (72.2) 34 (94.4) 34** (94.4) 30 (83.3)
CRh 14† (16.3) 7 (8.1) 9 (25) 2 (5.6) 2 (5.6) 1 (2.8)
CRi (without CRh) 1‡ (1.2) 1 (1.2) 0 (0) 0 (0) 0 (0) 0 (0)
Blast-free hypoplastic or aplastic
bone marrow (without CRi)
0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Partial remission 1 (1.2) 0 (0) 1 (2.8) 0 (0) 0 (0) 0 (0)
Nonresponse 1 (1.2) 1 (1.2) 0 (0) 0 (0) 0 (0) 0 (0)
Hematological relapse 0 (0) 6 (7) 0 (0) 0 (0) 0 (0) 2 (5.6)
Progressive disease 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 1 (2.8)
Unevaluable/no response data 0 (0) 8 (9.3) 0 (0) 0 (0) 0 (0) 2 (5.6)
CR/CRh/CRi 84 (97.7) 71 (82.6) 35 (97.2) 36 (100) 36 (100) 31 (86.1)
Best MRD response, n (%)
Evaluable MRD assessment, N1 72 49 30 23 30 14
MRD CR§ 44/72‖ (61.1) 29/49 (59.1) 22/30 (73.3) 21/23 (91.3) 24/30†† (80.0) 8/14 (57.1)
MRD remission§ 11/72{ (15.2) 3/49 (6.1) 4/30 (13.3) 1/23 (4.3) 3/30 (10.0) 3/14 (21.4)
No MRD remission§ 14/72# (19.4) 17/49 (34.6) 4/30 (13.3) 1/23 (4.3) 3/30 (10.0) 3/14 (21.4)
No MRD assessment 17/86 (16.3) 37/86 (43.0) 6/36 (16.7) 13/36 (36.1) 6/36 (16.7) 22/36 (61.1)
CR was defined as 5% or less bone marrow blasts and no evidence of disease and was further characterized according to the extent of recovery of peripheral blood counts as follows:
CR with full recovery (platelet count of .1003 103/mL and ANC of .1 3 103/mL), CRh (platelet count of .503 103/mL and ANC of .0.5 3 103/mL), or CRi (platelet count of .1003
103/mL or ANC of .1 3 103/mL). MRD response was defined as MRD level ,1024 measured by real-time quantitative PCR (or multicolor flow cytometry). MRD complete response was
defined as no detectable leukemic cells by quantitative PCR (or flow cytometry).
*Of the 69 patients with best response of CR before consolidation, 52 had best response of CR, 4 had CRh, 6 had hematological relapse, and 7 patients had unevaluable or no data
during consolidation (supplemental Table 2A).
†Of the 14 patients with best response of CRh before consolidation, 9 had best response of CR during consolidation (supplemental Table 2A).
‡This patient went on to achieve CR during blinatumomab consolidation therapy (supplemental Table 2A).
§Percentage with respect to N1.
‖Of the 44 patients who had MRD CR before consolidation, 25 had best response of MRD CR, 1 had MRD remission, 8 lost remission, and 10 had no MRD assessment during
consolidation (supplemental Table 3A).
{Of the 11 patients who had best response of MRD remission before consolidation, 2 had best response of MRD CR, 1 maintained MRD remission, and 8 had no MRD assessment
during consolidation (supplemental Table 3A).
#All 14 patients had no MRD assessment during consolidation (supplemental Table 3A).
**Of the 34 patients with best response of CR before maintenance, 30 had best response of CR, 2 relapsed, 1 had progressive disease, and 1 had unevaluable or no data during
maintenance (supplemental Table 2B).
††Of the 24 patients with best response of MRD complete response before maintenance, 8 had best response of MRD complete response, 1 had MRD remission, 2 had no MRD
remission, and 13 had no MRD assessment during maintenance (supplemental Table 3B).
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